{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:11:24Z","timestamp":1787062284849,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","award":["E-23334-02"],"award-info":[{"award-number":["E-23334-02"]}],"id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005860","name":"Helsefonden","doi-asserted-by":"publisher","award":["19-B-0063"],"award-info":[{"award-number":["19-B-0063"]}],"id":[{"id":"10.13039\/501100005860","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase og Ejnar Danielsens Fond","doi-asserted-by":"publisher","award":["18-10-0698"],"award-info":[{"award-number":["18-10-0698"]}],"id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009898","name":"Beckett-Fonden","doi-asserted-by":"publisher","award":["19-2-3490"],"award-info":[{"award-number":["19-2-3490"]}],"id":[{"id":"10.13039\/501100009898","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007444","name":"Einar Willumsen Foundation","doi-asserted-by":"publisher","award":["500028"],"award-info":[{"award-number":["500028"]}],"id":[{"id":"10.13039\/100007444","id-type":"DOI","asserted-by":"publisher"}]},{"name":"P. Carl Petersens Fond","award":["19102"],"award-info":[{"award-number":["19102"]}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["780989"],"award-info":[{"award-number":["780989"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Deferoxamine retinopathy is the informally designated term used to describe a characteristic pattern of outer retinal degeneration in iron-overloaded chronic anemia patients who are treated with deferoxamine. We hypothesize that insufficiently treated iron overloading and not only deferoxamine is the cause of the retinal degeneration. Our case report is based on exposure histories of two anemia patients and literature review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Both anemia patients presented with bilateral visual loss secondary to photoreceptor and retinal pigment epithelium degeneration. Chart review showed that visual loss came after a year-long slow, and rather monotonous rise in plasma ferritin concentrations, with no obvious relation to iron chelator exposure. In one patient, the onset of symptomatic visual loss came after a bout of fever followed by two additional febrile episodes, all accompanied by plasma ferritin spikes. Adjustment of iron chelation therapy did not improve visual function. Experimental studies clearly show that both systemic and intraocular exposure to iron ions can induce retinal degeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The available evidence indicates that retinal degeneration in chronic anemia patients treated by deferoxamine is cause by insufficient iron chelation, not by deferoxamine. The actual role of iron chelating agents may be to promote a long enough survival to allow the slow development of retinal siderosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-021-02030-1","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T09:03:26Z","timestamp":1626167006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Iron overload and iron chelating agent exposure in anemia-associated outer retinal degeneration: a case report and review of the literature"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5855-4733","authenticated-orcid":false,"given":"Mohamed","family":"Belmouhand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Eckmann-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Ilginis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Birgitte","family":"Lein\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Kok","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"issue":"10","key":"2030_CR1","first-page":"1187","volume":"89","author":"C Borgna-Pignatti","year":"2004","unstructured":"Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187\u201393.","journal-title":"Haematologica."},{"issue":"7","key":"2030_CR2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1097\/IAE.0000000000000073","volume":"34","author":"F Viola","year":"2014","unstructured":"Viola F, Barteselli G, Dell\u02bcArti L, et al. Multimodal imaging in deferoxamine retinopathy. Retina. 2014;34(7):1428\u201338. https:\/\/doi.org\/10.1097\/IAE.0000000000000073.","journal-title":"Retina."},{"issue":"8343","key":"2030_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/s0140-6736(83)90170-8","volume":"2","author":"SC Davies","year":"1983","unstructured":"Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983;2(8343):181\u20134. https:\/\/doi.org\/10.1016\/s0140-6736(83)90170-8.","journal-title":"Lancet."},{"key":"2030_CR4","doi-asserted-by":"publisher","first-page":"249617","DOI":"10.1155\/2015\/249617","volume":"2015","author":"M Di Nicola","year":"2015","unstructured":"Di Nicola M, Barteselli G, Dell'Arti L, Ratiglia R, Viola F. Functional and structural abnormalities in Deferoxamine retinopathy: a review of the literature. Biomed Res Int. 2015;2015:249617\u20132. https:\/\/doi.org\/10.1155\/2015\/249617.","journal-title":"Biomed Res Int"},{"issue":"2","key":"2030_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/ICB.0000000000000013","volume":"8","author":"L Van Bol","year":"2014","unstructured":"Van Bol L, Alami A, Benghiat FS, Rasquin F. Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: report of two cases. Retinal Cases and Brief Reports. 2014;8(2):97\u2013102. https:\/\/doi.org\/10.1097\/ICB.0000000000000013.","journal-title":"Retinal Cases and Brief Reports"},{"issue":"4","key":"2030_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/ICB.0000000000000059","volume":"8","author":"R Gelman","year":"2014","unstructured":"Gelman R, Kiss S, Tsang SH. Multimodal imaging in a case of deferoxamine-induced maculopathy. Retin Cases Brief Rep. 2014;8(4):306\u20139. https:\/\/doi.org\/10.1097\/ICB.0000000000000059.","journal-title":"Retin Cases Brief Rep"},{"issue":"1","key":"2030_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12886-018-0911-2","volume":"18","author":"CD Georgakopoulos","year":"2018","unstructured":"Georgakopoulos CD, Tsapardoni F, Kostopoulou EV, Makri OE. Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature. BMC Ophthalmol. 2018;18(1):246. https:\/\/doi.org\/10.1186\/s12886-018-0911-2.","journal-title":"BMC Ophthalmol"},{"key":"2030_CR8","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.2147\/OPTH.S300974","volume":"15","author":"R Nuzzi","year":"2021","unstructured":"Nuzzi R, Geronazzo G, Tridico F, Nuzzi A, Caselgrandi P, Piga AG. Long-term effects of Iron chelating agents on ocular function in patients with thalassemia major. Clin Ophthalmol. 2021;15:2099\u2013109. https:\/\/doi.org\/10.2147\/OPTH.S300974.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"2030_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.survophthal.2015.08.005","volume":"61","author":"DL Bhoiwala","year":"2016","unstructured":"Bhoiwala DL, Dunaief JL. Retinal abnormalities in \u03b2-thalassemia major. Surv Ophthalmol. 2016;61(1):33\u201350. https:\/\/doi.org\/10.1016\/j.survophthal.2015.08.005.","journal-title":"Surv Ophthalmol"},{"key":"2030_CR10","doi-asserted-by":"publisher","unstructured":"Kami\u0144ska A, Romano GL, Rejdak R, et al. Influence of Trace Elements on Neurodegenerative Diseases of The Eye-The Glaucoma Model. Int J Mol Sci. 2021;22(9). https:\/\/doi.org\/10.3390\/ijms22094323.","DOI":"10.3390\/ijms22094323"},{"issue":"Pt 4","key":"2030_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1242\/jcs.92.4.655","volume":"92","author":"RC Hunt","year":"1989","unstructured":"Hunt RC, Dewey A, Davis AA. Transferrin receptors on the surfaces of retinal pigment epithelial cells are associated with the cytoskeleton. J Cell Sci. 1989;92(Pt 4):655\u201366. https:\/\/doi.org\/10.1242\/jcs.92.4.655.","journal-title":"J Cell Sci"},{"issue":"6","key":"2030_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.preteyeres.2007.07.004","volume":"26","author":"X He","year":"2007","unstructured":"He X, Hahn P, Iacovelli J, Wong R, King C, Bhisitkul R, et al. Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res. 2007;26(6):649\u201373. https:\/\/doi.org\/10.1016\/j.preteyeres.2007.07.004.","journal-title":"Prog Retin Eye Res"},{"key":"2030_CR13","volume-title":"Guidelines for the clinical Management of Thalassaemia, 2nd revised edition. Thalassaemia International Federation","author":"MDCA Cappellini","year":"2008","unstructured":"Cappellini MD CA, Eleftheriou A, et al. Guidelines for the clinical Management of Thalassaemia, 2nd revised edition. Thalassaemia International Federation; 2008."},{"key":"2030_CR14","doi-asserted-by":"publisher","unstructured":"Wu CH, Yang CP, Lai CC, Wu WC, Chen YH Deferoxamine retinopathy: spectral domain-optical coherence tomography findings BMC Ophthalmol 2014;14:88. doi:https:\/\/doi.org\/10.1186\/1471-2415-14-88, 1.","DOI":"10.1186\/1471-2415-14-88"},{"issue":"5","key":"2030_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/iub.326","volume":"62","author":"JP Gnana-Prakasam","year":"2010","unstructured":"Gnana-Prakasam JP, Martin PM, Smith SB, Ganapathy V. Expression and function of iron-regulatory proteins in retina. IUBMB Life. 2010;62(5):363\u201370. https:\/\/doi.org\/10.1002\/iub.326.","journal-title":"IUBMB Life"},{"issue":"2","key":"2030_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/icb.0000000000000135","volume":"9","author":"J Zerbib","year":"2015","unstructured":"Zerbib J, Pierre-Kahn V, Sikorav A, Oubraham H, Sayag D, Lobstein F, et al. Unusual retinopathy associated with hemochromatosis. Retin Cases Brief Rep. 2015;9(2):190\u20134. https:\/\/doi.org\/10.1097\/icb.0000000000000135.","journal-title":"Retin Cases Brief Rep."},{"issue":"4","key":"2030_CR17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/0002-9394(72)90826-4","volume":"74","author":"L Masciulli","year":"1972","unstructured":"Masciulli L, Anderson DR, Charles S. Experimental ocular siderosis in the squirrel monkey. Am J Ophthalmol. 1972;74(4):638\u201361. https:\/\/doi.org\/10.1016\/0002-9394(72)90826-4.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"2030_CR18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/archopht.1977.04450060138014","volume":"95","author":"SS Declercq","year":"1977","unstructured":"Declercq SS, Meredith PC, Rosenthal AR. Experimental siderosis in the rabbit: correlation between electroretinography and histopathology. Arch Ophthalmol. 1977;95(6):1051\u20138. https:\/\/doi.org\/10.1001\/archopht.1977.04450060138014.","journal-title":"Arch Ophthalmol"},{"key":"2030_CR19","doi-asserted-by":"publisher","first-page":"7272465","DOI":"10.1155\/2016\/7272465","volume":"2016","author":"NB Kannan","year":"2016","unstructured":"Kannan NB, Adenuga OO, Rajan RP, Ramasamy K. Management of Ocular Siderosis: visual outcome and Electroretinographic changes. J Ophthalmol. 2016;2016:7272465. https:\/\/doi.org\/10.1155\/2016\/7272465.","journal-title":"J Ophthalmol"},{"issue":"8","key":"2030_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/bjo.64.8.626","volume":"64","author":"SS Declercq","year":"1980","unstructured":"Declercq SS. Desferrioxamine in ocular siderosis: a long-term electrophysiological evaluation. Br J Ophthalmol. 1980;64(8):626\u20139. https:\/\/doi.org\/10.1136\/bjo.64.8.626.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"2030_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1167\/iovs.10-6207","volume":"52","author":"M Hadziahmetovic","year":"2011","unstructured":"Hadziahmetovic M, Song Y, Wolkow N, Iacovelli J, Grieco S, Lee J, et al. The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration. Invest Ophthalmol Vis Sci. 2011;52(2):959\u201368. https:\/\/doi.org\/10.1167\/iovs.10-6207.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"2030_CR22","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1167\/iovs.14-14568","volume":"55","author":"D Song","year":"2014","unstructured":"Song D, Zhao L, Li Y, Hadziahmetovic M, Song Y, Connelly J, et al. The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice. Invest Ophthalmol Vis Sci. 2014;55(7):4525\u201332. https:\/\/doi.org\/10.1167\/iovs.14-14568.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"38","key":"2030_CR23","doi-asserted-by":"publisher","first-page":"13850","DOI":"10.1073\/pnas.0405146101","volume":"101","author":"P Hahn","year":"2004","unstructured":"Hahn P, Qian Y, Dentchev T, Chen L, Beard J, Harris ZL, et al. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc Natl Acad Sci U S A. 2004;101(38):13850\u20135. https:\/\/doi.org\/10.1073\/pnas.0405146101.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2030_CR24","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1038\/s41598-018-21276-2","volume":"8","author":"K Chaudhary","year":"2018","unstructured":"Chaudhary K, Promsote W, Ananth S, Veeranan-Karmegam R, Tawfik A, Arjunan P, et al. Iron overload accelerates the progression of diabetic retinopathy in association with increased retinal renin expression. Sci Rep. 2018;8(1):3025. https:\/\/doi.org\/10.1038\/s41598-018-21276-2.","journal-title":"Sci Rep"},{"key":"2030_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fnagi.2013.00024","volume":"5","author":"D Song","year":"2013","unstructured":"Song D, Dunaief JL. Retinal iron homeostasis in health and disease. Front Aging Neurosci. 2013;5:24. https:\/\/doi.org\/10.3389\/fnagi.2013.00024.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"2030_CR26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.exer.2009.10.013","volume":"90","author":"S Thaler","year":"2010","unstructured":"Thaler S, Fiedorowicz M, Rejdak R, Choragiewicz TJ, Sulejczak D, Stopa P, et al. Neuroprotective effects of tempol on retinal ganglion cells in a partial optic nerve crush rat model with and without iron load. Exp Eye Res. 2010;90(2):254\u201360. https:\/\/doi.org\/10.1016\/j.exer.2009.10.013.","journal-title":"Exp Eye Res"},{"key":"2030_CR27","doi-asserted-by":"publisher","first-page":"108292","DOI":"10.1016\/j.exer.2020.108292","volume":"202","author":"A Valen\u00e7a","year":"2021","unstructured":"Valen\u00e7a A, Mendes-Jorge L, Bonet A, Catita J, Ramos D, Jose-Cunilleras E, et al. TIM2 modulates retinal iron levels and is involved in blood-retinal barrier breakdown. Exp Eye Res. 2021;202:108292. https:\/\/doi.org\/10.1016\/j.exer.2020.108292.","journal-title":"Exp Eye Res"},{"key":"2030_CR28","doi-asserted-by":"publisher","first-page":"108642","DOI":"10.1016\/j.exer.2021.108642","volume":"209","author":"Q Song","year":"2021","unstructured":"Song Q, Zhang F, Han X, Yang Y, Zhao Y, Duan J. Ameliorative effects and mechanisms of salvianic acid a on retinal iron overload in vivo and in vitro. Exp Eye Res. 2021;209:108642. https:\/\/doi.org\/10.1016\/j.exer.2021.108642.","journal-title":"Exp Eye Res"},{"key":"2030_CR29","doi-asserted-by":"publisher","first-page":"109690","DOI":"10.1016\/j.biopha.2019.109690","volume":"122","author":"Q Song","year":"2020","unstructured":"Song Q, Zhao Y, Li Q, Han X, Duan J. Puerarin protects against iron overload-induced retinal injury through regulation of iron-handling proteins. Biomed Pharmacother. 2020;122:109690. https:\/\/doi.org\/10.1016\/j.biopha.2019.109690.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"2030_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Cao F, Yin H-L, et al. Ferroptosis: past, present and future. Cell Death & Disease. 2020;11(2):88. https:\/\/doi.org\/10.1038\/s41419-020-2298-2.","journal-title":"Cell Death & Disease"},{"key":"2030_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.exer.2018.08.019","volume":"181","author":"K Totsuka","year":"2019","unstructured":"Totsuka K, Ueta T, Uchida T, Roggia MF, Nakagawa S, Vavvas DG, et al. Oxidative stress induces ferroptotic cell death in retinal pigment epithelial cells. Exp Eye Res. 2019;181:316\u201324. https:\/\/doi.org\/10.1016\/j.exer.2018.08.019.","journal-title":"Exp Eye Res"},{"key":"2030_CR32","doi-asserted-by":"publisher","first-page":"bcr2013009205","DOI":"10.1136\/bcr-2013-009205","volume":"2013","author":"HS Walia","year":"2013","unstructured":"Walia HS, Yan J. Reversible retinopathy associated with oral deferasirox therapy. BMJ Case Rep. 2013;2013:bcr2013009205. https:\/\/doi.org\/10.1136\/bcr-2013-009205.","journal-title":"BMJ Case Rep"},{"issue":"4","key":"2030_CR33","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1111\/j.1755-3768.2011.02276.x","volume":"90","author":"IC Munch","year":"2012","unstructured":"Munch IC, Traustason S, Olgaard K, Larsen M. Acute macular neuroretinopathy in relation to anti-thymocyte globulin infusion. Acta Ophthalmol. 2012;90(4):e321\u20132. https:\/\/doi.org\/10.1111\/j.1755-3768.2011.02276.x.","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"2030_CR34","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1167\/iovs.08-2850","volume":"50","author":"H Chen","year":"2009","unstructured":"Chen H, Lukas TJ, Du N, Suyeoka G, Neufeld AH. Dysfunction of the retinal pigment epithelium with age: increased iron decreases phagocytosis and lysosomal activity. Invest Ophthalmol Vis Sci. 2009;50(4):1895\u2013902. https:\/\/doi.org\/10.1167\/iovs.08-2850.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02030-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-021-02030-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02030-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T09:13:32Z","timestamp":1626167612000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-021-02030-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2030"],"URL":"https:\/\/doi.org\/10.1186\/s12886-021-02030-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"1 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not necessary for this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Both study participants gave their oral and written informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ML has consulted, spoken or been a trial investigator for Novartis, Chiesi, Allergan, Bayer, Alcon, AbbVie, Biogen, Novo Nordisk, Eli Lilly, Spark Therapeutics, Nightstar, Sanofi and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}